A carregar...
Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
We evaluated the relationship between benralizumab (30 mg every 4 and 8 weeks (Q4W, Q8W)) pharmacokinetic (PK) exposure and end points of asthma exacerbation rates (AERs) and change from baseline in prebronchodilator forced expiratory volume in 1 second (FEV (1)) for patients with severe, uncontroll...
Na minha lista:
| Publicado no: | Clin Pharmacol Ther |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6767326/ https://ncbi.nlm.nih.gov/pubmed/30661249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1371 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|